Cloned (Comment) | Organism |
---|---|
gene coaD, recombinant expression in Escherichia coli strain BL21(DE3) | Homo sapiens |
gene coaD, recombinant overexpression in Escherichia coli strain BL21(DE3) | Escherichia coli |
gene coaD, recombinant overexpression in Escherichia coli strain BL21(DE3) | Haemophilus influenzae |
gene coaD, recombinant overexpression in Escherichia coli strain BL21(DE3) | Streptococcus mutans |
gene coaD, recombinant overexpression of wild-type and mutant enzymes in Escherichia coli strain BL21(DE3) | Staphylococcus aureus |
gene coaD, recombinant overexpression of wild/type and mutant enzymes in Escherichia coli strain BL21 pLysS(DE3), overexpression of Streptococcus pneumoniae coaD in Streptococcus pneumoniae is achieved by driving expression from the galU promoter | Streptococcus pneumoniae |
Crystallization (Comment) | Organism |
---|---|
enzyme from Staphylococcus aureus subsp. aureus MW2 in complex with inhibitors, vapour diffusion method, mixing of 0.0025 ml of protein solution with 0.0025 ml of reservoir solution containing 14% to 19% PEG 3350, 200 mM ammonium sulfate, and 0.1 M propionic acid cacodylate Bis-Tris propane buffer, pH 7.5, 20°C, 5-7 days, X-ray diffraction structure determination and analysis at 1.72-2.38 A resolution, molecular replacement and modelling of inhibitor binding | Staphylococcus aureus |
Protein Variants | Comment | Organism |
---|---|---|
F8L | the enzyme mutant is less sensitive to inhibition by compound D compared to the wild-type enzyme | Streptococcus pneumoniae |
N106H | the enzyme mutant is less sensitive to inhibition by compound D compared to the wild-type enzyme | Staphylococcus aureus |
N106Y | the enzyme mutant is less sensitive to inhibition by compound D compared to the wild-type enzyme | Staphylococcus aureus |
N107H | the enzyme mutant is less sensitive to inhibition by compound D compared to the wild-type enzyme | Streptococcus pneumoniae |
T117N | the enzyme mutant is less sensitive to inhibition by compound D compared to the wild-type enzyme | Streptococcus pneumoniae |
V136F | the enzyme mutant is less sensitive to inhibition by compound D compared to the wild-type enzyme | Staphylococcus aureus |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(1S,2S)-N-(3,4-dichlorobenzyl)-2-(4,6-dimethoxypyrimidin-2-yl)cyclohexanecarboxamide | - |
Haemophilus influenzae | |
(1S,2S)-N-(3,4-dichlorobenzyl)-2-(4,6-dimethoxypyrimidin-2-yl)cyclohexanecarboxamide | - |
Homo sapiens | |
(1S,2S)-N-(3,4-dichlorobenzyl)-2-(4,6-dimethoxypyrimidin-2-yl)cyclohexanecarboxamide | - |
Staphylococcus aureus | |
(1S,2S)-N-(3,4-dichlorobenzyl)-2-(4,6-dimethoxypyrimidin-2-yl)cyclohexanecarboxamide | - |
Streptococcus pneumoniae | |
(1S,2S)-N-(3-chlorobenzyl)-2-(4,6-dimethoxypyrimidin-2-yl)cyclohexanecarboxamide | - |
Haemophilus influenzae | |
(1S,2S)-N-(3-chlorobenzyl)-2-(4,6-dimethoxypyrimidin-2-yl)cyclohexanecarboxamide | - |
Staphylococcus aureus | |
(1S,2S)-N-(3-chlorobenzyl)-2-(4,6-dimethoxypyrimidin-2-yl)cyclohexanecarboxamide | - |
Streptococcus mutans | |
(1S,2S)-N-(3-chlorobenzyl)-2-(4,6-dimethoxypyrimidin-2-yl)cyclohexanecarboxamide | - |
Streptococcus pneumoniae | |
2'-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6'-ethyl-4-hydroxy-6-oxo-1,6-dihydro-2,4'-bipyrimidine-5-carboxamide | - |
Enterococcus faecium | |
2'-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6'-ethyl-4-hydroxy-6-oxo-1,6-dihydro-2,4'-bipyrimidine-5-carboxamide | - |
Escherichia coli | |
2'-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6'-ethyl-4-hydroxy-6-oxo-1,6-dihydro-2,4'-bipyrimidine-5-carboxamide | - |
Haemophilus influenzae | |
2'-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6'-ethyl-4-hydroxy-6-oxo-1,6-dihydro-2,4'-bipyrimidine-5-carboxamide | slight inhibition in vivo | Homo sapiens | |
2'-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6'-ethyl-4-hydroxy-6-oxo-1,6-dihydro-2,4'-bipyrimidine-5-carboxamide | - |
Staphylococcus aureus | |
2'-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6'-ethyl-4-hydroxy-6-oxo-1,6-dihydro-2,4'-bipyrimidine-5-carboxamide | - |
Streptococcus mutans | |
2'-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6'-ethyl-4-hydroxy-6-oxo-1,6-dihydro-2,4'-bipyrimidine-5-carboxamide | - |
Streptococcus pneumoniae | |
2'-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6'-ethyl-4-hydroxy-6-oxo-1,6-dihydro-2,4'-bipyrimidine-5-carboxamide | - |
Streptococcus pyogenes | |
2-[(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)sulfanyl]-1H-imidazole-5-carboxylic acid | - |
Escherichia coli | |
2-[(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)sulfanyl]-1H-imidazole-5-carboxylic acid | - |
Haemophilus influenzae | |
2-[(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)sulfanyl]-1H-imidazole-5-carboxylic acid | - |
Staphylococcus aureus | |
2-[(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)sulfanyl]-1H-imidazole-5-carboxylic acid | - |
Streptococcus pneumoniae | |
3-[3-(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)-1,2,4-oxadiazol-5-yl]propanoic acid | slight inhibition in vivo | Enterococcus faecium | |
3-[3-(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)-1,2,4-oxadiazol-5-yl]propanoic acid | - |
Escherichia coli | |
3-[3-(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)-1,2,4-oxadiazol-5-yl]propanoic acid | - |
Haemophilus influenzae | |
3-[3-(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)-1,2,4-oxadiazol-5-yl]propanoic acid | - |
Homo sapiens | |
3-[3-(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)-1,2,4-oxadiazol-5-yl]propanoic acid | - |
Staphylococcus aureus | |
3-[3-(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)-1,2,4-oxadiazol-5-yl]propanoic acid | - |
Streptococcus pneumoniae | |
3-[3-(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)-1,2,4-oxadiazol-5-yl]propanoic acid | - |
Streptococcus pyogenes | |
additional information | compound library screening, the series of reversible inhibitors show inhibition of cell growth of Gram-positive species but not of Candida albicans. MIC values, overview. Compounds HTS hit, A, B, C, and D show poor inhibition in vivo | Candida albicans | |
additional information | compound library screening, the potency of the series is optimized using structure-based design, resulting in inhibition of cell growth of Gram-positive species. MIC values, overview | Enterococcus faecium | |
additional information | compound library screening, the potency of the series is optimized using structure-based design, resulting in inhibition of cell growth of Gram-positive species. Levels of inhibitory activity of compounds against Escherichia coli PPAT are measured in the reverse direction, MIC values, overview | Escherichia coli | |
additional information | compound library screening, the potency of the series is optimized using structure-based design, resulting in inhibition of cell growth of Gram-positive species. Levels of inhibitory activity of compounds against Haemophilus influenzae PPAT are measured in the reverse direction, MIC values, overview | Haemophilus influenzae | |
additional information | compound library screening, the series of reversible inhibitors show inhibition of cell growth of Gram-positive species but no or only slight inhibition of the human A-549 tumor cells, MIC values, overview. levels of inhibitory activity of compounds against Homo sapiens PPAT are measured in the forward direction. Only compound C shows poor inhibition in vivo | Homo sapiens | |
additional information | compound library screening, mode-of-inhibition studies with Staphylococcus aureus PPAT demonstrate representatives of this series to be reversible inhibitors competitive versus phosphopantetheine and uncompetitive versus ATP, binding to the enzyme-ATP complex, overview. The potency of the series is optimized using structure-based design, resulting in inhibition of cell growth of Gram-positive species. Levels of inhibitory activity of compounds against Staphylococcus aureus PPAT are measured in the forward direction, MIC values, mechanism of inhibition, overview | Staphylococcus aureus | |
additional information | compound library screening, the potency of the series is optimized using structure-based design, resulting in inhibition of cell growth of Gram-positive species. Levels of inhibitory activity of compounds against Streptococcus mutans PPAT are measured in the reverse direction, MIC values, overview | Streptococcus mutans | |
additional information | ccompound library screening, mode-of-inhibition studies with Streptococcus pneumoniae PPAT demonstrate representatives of this series to be reversible inhibitors competitive versus phosphopantetheine and uncompetitive versus ATP, binding to the enzyme-ATP complex, overview. The potency of the series is optimized using structure-based design, resulting in inhibition of cell growth of Gram-positive species, killing kinetic assays using Staphylococcus aureus strains ARC516 and a LytA- for Streptococcus pneumoniae. Levels of inhibitory activity of compounds against Streptococcus pneumoniae PPAT are measured in the forward direction. MIC values, mechanism of inhibition, overview | Streptococcus pneumoniae | |
additional information | compound library screening, the potency of the series is optimized using structure-based design, resulting in inhibition of cell growth of Gram-positive species. MIC values, overview | Streptococcus pyogenes |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
ATP + pantetheine 4'-phosphate | Staphylococcus aureus | - |
diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | Streptococcus pyogenes | - |
diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | Enterococcus faecium | - |
diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | Escherichia coli | - |
diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | Homo sapiens | - |
diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | Candida albicans | - |
diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | Streptococcus pneumoniae | - |
diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | Haemophilus influenzae | - |
diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | Streptococcus mutans | - |
diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | Enterococcus faecium ARC521 | - |
diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | Streptococcus pyogenes ARC838 | - |
diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | Haemophilus influenzae KW20 | - |
diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | Streptococcus mutans UA159 | - |
diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | Staphylococcus aureus RN4220 | - |
diphosphate + 3'-dephospho-CoA | - |
r |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Candida albicans | B9WCR8 | strain CD36; gene coaD | - |
Enterococcus faecium | - |
gene coaD | - |
Enterococcus faecium ARC521 | - |
gene coaD | - |
Escherichia coli | P0A6I6 | MG1655, gene coaD | - |
Haemophilus influenzae | P44805 | gene coaD | - |
Haemophilus influenzae KW20 | P44805 | gene coaD | - |
Homo sapiens | Q06203 | gene coaD | - |
Staphylococcus aureus | - |
gene coaD | - |
Staphylococcus aureus RN4220 | - |
gene coaD | - |
Streptococcus mutans | Q8DVH2 | gene coaD | - |
Streptococcus mutans UA159 | Q8DVH2 | gene coaD | - |
Streptococcus pneumoniae | Q8DNE6 | gene coaD | - |
Streptococcus pyogenes | - |
gene coaD | - |
Streptococcus pyogenes ARC838 | - |
gene coaD | - |
Purification (Comment) | Organism |
---|---|
recombinant enzyme PPAT from Escherichia coli strain BL21(DE3) to over 95% purity | Escherichia coli |
recombinant enzyme PPAT from Escherichia coli strain BL21(DE3) to over 95% purity | Homo sapiens |
recombinant enzyme PPAT from Escherichia coli strain BL21(DE3) to over 95% purity | Haemophilus influenzae |
recombinant enzyme PPAT from Escherichia coli strain BL21(DE3) to over 95% purity | Streptococcus mutans |
recombinant wild-type and mutant PPAT enzymes from Escherichia coli strain BL21 pLysS(DE3) to over 95% purity | Streptococcus pneumoniae |
recombinant wild-type and mutant PPAT enzymes from Escherichia coli strain BL21(DE3) to over 90% purity | Staphylococcus aureus |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
A-549 cell | - |
Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
ATP + pantetheine 4'-phosphate | - |
Staphylococcus aureus | diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | - |
Streptococcus pyogenes | diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | - |
Enterococcus faecium | diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | - |
Escherichia coli | diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | - |
Homo sapiens | diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | - |
Candida albicans | diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | - |
Streptococcus pneumoniae | diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | - |
Haemophilus influenzae | diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | - |
Streptococcus mutans | diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | - |
Enterococcus faecium ARC521 | diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | - |
Streptococcus pyogenes ARC838 | diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | - |
Haemophilus influenzae KW20 | diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | - |
Streptococcus mutans UA159 | diphosphate + 3'-dephospho-CoA | - |
r | |
ATP + pantetheine 4'-phosphate | - |
Staphylococcus aureus RN4220 | diphosphate + 3'-dephospho-CoA | - |
r |
Synonyms | Comment | Organism |
---|---|---|
4-phosphopantetheine adenylyltransferase | - |
Staphylococcus aureus |
4-phosphopantetheine adenylyltransferase | - |
Streptococcus pyogenes |
4-phosphopantetheine adenylyltransferase | - |
Enterococcus faecium |
4-phosphopantetheine adenylyltransferase | - |
Escherichia coli |
4-phosphopantetheine adenylyltransferase | - |
Homo sapiens |
4-phosphopantetheine adenylyltransferase | - |
Candida albicans |
4-phosphopantetheine adenylyltransferase | - |
Streptococcus pneumoniae |
4-phosphopantetheine adenylyltransferase | - |
Haemophilus influenzae |
4-phosphopantetheine adenylyltransferase | - |
Streptococcus mutans |
PPAT | - |
Staphylococcus aureus |
PPAT | - |
Streptococcus pyogenes |
PPAT | - |
Enterococcus faecium |
PPAT | - |
Escherichia coli |
PPAT | - |
Homo sapiens |
PPAT | - |
Candida albicans |
PPAT | - |
Streptococcus pneumoniae |
PPAT | - |
Haemophilus influenzae |
PPAT | - |
Streptococcus mutans |
Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|
22 | - |
assay at room temperature | Staphylococcus aureus |
22 | - |
assay at room temperature | Streptococcus pyogenes |
22 | - |
assay at room temperature | Enterococcus faecium |
22 | - |
assay at room temperature | Escherichia coli |
22 | - |
assay at room temperature | Homo sapiens |
22 | - |
assay at room temperature | Candida albicans |
22 | - |
assay at room temperature | Streptococcus pneumoniae |
22 | - |
assay at room temperature | Haemophilus influenzae |
22 | - |
assay at room temperature | Streptococcus mutans |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
7 | - |
assay at | Staphylococcus aureus |
7 | - |
assay at | Streptococcus pyogenes |
7 | - |
assay at | Enterococcus faecium |
7 | - |
assay at | Escherichia coli |
7 | - |
assay at | Homo sapiens |
7 | - |
assay at | Candida albicans |
7 | - |
assay at | Streptococcus pneumoniae |
7 | - |
assay at | Haemophilus influenzae |
7 | - |
assay at | Streptococcus mutans |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.000000065 | - |
pH 7.0, 22°C, recombinant enzyme | Streptococcus pneumoniae | 2'-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6'-ethyl-4-hydroxy-6-oxo-1,6-dihydro-2,4'-bipyrimidine-5-carboxamide | |
0.00000013 | - |
pH 7.0, 22°C, recombinant enzyme | Streptococcus pneumoniae | 3-[3-(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)-1,2,4-oxadiazol-5-yl]propanoic acid | |
0.00000041 | - |
pH 7.0, 22°C, recombinant enzyme | Staphylococcus aureus | 3-[3-(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)-1,2,4-oxadiazol-5-yl]propanoic acid | |
0.00000087 | - |
pH 7.0, 22°C, recombinant enzyme | Staphylococcus aureus | 2'-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6'-ethyl-4-hydroxy-6-oxo-1,6-dihydro-2,4'-bipyrimidine-5-carboxamide | |
0.0000026 | - |
pH 7.0, 22°C, recombinant enzyme | Streptococcus mutans | 2'-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6'-ethyl-4-hydroxy-6-oxo-1,6-dihydro-2,4'-bipyrimidine-5-carboxamide | |
0.00004 | - |
pH 7.0, 22°C, recombinant enzyme | Streptococcus pneumoniae | 2-[(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)sulfanyl]-1H-imidazole-5-carboxylic acid | |
0.000098 | - |
pH 7.0, 22°C, recombinant enzyme | Streptococcus mutans | (1S,2S)-N-(3-chlorobenzyl)-2-(4,6-dimethoxypyrimidin-2-yl)cyclohexanecarboxamide | |
0.00011 | - |
pH 7.0, 22°C, recombinant enzyme | Escherichia coli | 2'-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6'-ethyl-4-hydroxy-6-oxo-1,6-dihydro-2,4'-bipyrimidine-5-carboxamide | |
0.00012 | - |
pH 7.0, 22°C, recombinant enzyme | Haemophilus influenzae | 2'-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6'-ethyl-4-hydroxy-6-oxo-1,6-dihydro-2,4'-bipyrimidine-5-carboxamide | |
0.000205 | - |
pH 7.0, 22°C, recombinant enzyme | Streptococcus pneumoniae | (1S,2S)-N-(3-chlorobenzyl)-2-(4,6-dimethoxypyrimidin-2-yl)cyclohexanecarboxamide | |
0.00033 | - |
pH 7.0, 22°C, recombinant enzyme | Staphylococcus aureus | (1S,2S)-N-(3,4-dichlorobenzyl)-2-(4,6-dimethoxypyrimidin-2-yl)cyclohexanecarboxamide | |
0.00033 | - |
pH 7.0, 22°C, recombinant enzyme | Escherichia coli | 3-[3-(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)-1,2,4-oxadiazol-5-yl]propanoic acid | |
0.00049 | - |
pH 7.0, 22°C, recombinant enzyme | Staphylococcus aureus | 2-[(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)sulfanyl]-1H-imidazole-5-carboxylic acid | |
0.00074 | - |
pH 7.0, 22°C, recombinant enzyme | Haemophilus influenzae | 3-[3-(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)-1,2,4-oxadiazol-5-yl]propanoic acid | |
0.00086 | - |
pH 7.0, 22°C, recombinant enzyme | Haemophilus influenzae | (1S,2S)-N-(3,4-dichlorobenzyl)-2-(4,6-dimethoxypyrimidin-2-yl)cyclohexanecarboxamide | |
0.0048 | - |
pH 7.0, 22°C, recombinant enzyme | Escherichia coli | 2-[(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)sulfanyl]-1H-imidazole-5-carboxylic acid | |
0.005 | - |
pH 7.0, 22°C, recombinant enzyme | Homo sapiens | (1S,2S)-N-(3,4-dichlorobenzyl)-2-(4,6-dimethoxypyrimidin-2-yl)cyclohexanecarboxamide | |
0.0073 | - |
pH 7.0, 22°C, recombinant enzyme | Staphylococcus aureus | (1S,2S)-N-(3-chlorobenzyl)-2-(4,6-dimethoxypyrimidin-2-yl)cyclohexanecarboxamide | |
0.0088 | - |
pH 7.0, 22°C, recombinant enzyme | Haemophilus influenzae | (1S,2S)-N-(3-chlorobenzyl)-2-(4,6-dimethoxypyrimidin-2-yl)cyclohexanecarboxamide | |
0.0095 | - |
pH 7.0, 22°C, recombinant enzyme | Haemophilus influenzae | 2-[(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)sulfanyl]-1H-imidazole-5-carboxylic acid | |
0.024 | - |
pH 7.0, 22°C, recombinant enzyme | Homo sapiens | 2'-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6'-ethyl-4-hydroxy-6-oxo-1,6-dihydro-2,4'-bipyrimidine-5-carboxamide | |
0.2 | - |
pH 7.0, 22°C, recombinant enzyme | Homo sapiens | 3-[3-(2-[(1S,2S)-2-[(3,4-dichlorobenzyl)carbamoyl]cyclohexyl]-6-ethylpyrimidin-4-yl)-1,2,4-oxadiazol-5-yl]propanoic acid |
General Information | Comment | Organism |
---|---|---|
malfunction | enzyme inhibition causes growth suppression of the bacteria | Streptococcus pyogenes |
malfunction | enzyme inhibition causes growth suppression of the bacteria | Enterococcus faecium |
malfunction | enzyme inhibition causes growth suppression of the bacteria | Streptococcus mutans |
malfunction | enzyme inhibition causes growth suppression of the bacteria, e.g. Escherichia coli strain ARC534, phenotype of enzyme knockout mutant Escherichia coli strain W3110, overview | Escherichia coli |
malfunction | enzyme inhibition causes growth suppression of the bacteria, e.g. of Haemophilus influenzae strain ATCC 51907 | Haemophilus influenzae |
malfunction | enzyme inhibition causes growth suppression of the bacteria, e.g. of Staphylococcus aureus strain ARC516 | Staphylococcus aureus |
malfunction | enzyme inhibition causes growth suppression of the bacteria, e.g. of Streptococcus pneumoniae strains D39 and ATCC 10813 | Streptococcus pneumoniae |
malfunction | enzyme inhibition causes growth suppression of the cells | Candida albicans |